Alessandro Aiuti, MD, PhD, on Durable, Clinically Meaningful Efficacy of Arsa-Cel in Metachromatic Leukodystrophy
The deputy director, clinical research, San Raffaele Telethon Institute for gene therapy, discussed long-term follow-up data of up to 12 years.
“This represents the proof of principle that ex vivo lentiviral gene therapy into stem cells can correct a lysosomal storage disorder and this has been further applied to mucopolysaccharidosis type one... and could be applicable to other lysosomal storage disorders and we're working on new diseases to bring this approach of enzyme overexpression correction to."
Atidarsagene autotemcel (arsa-cel) shows a favorable benefit-risk profile with clinically meaningful, durable reductions in disease progression in patients with early-onset metachromatic leukodystrophy (MLD). Long-term data from across 2 prospective clinical trials (n=30) and expanded access frameworks (n=9), comprising up to 12 years of follow-up, were presented at
CGTLive® spoke with Aiuti to learn more about the updated data what it means for the field. He also discussed other investigations ongoing with arsa-cel for MLD as well as for other diseases, including mucopolysaccharidosis type 1. Arsa-cel was approved by the FDA under the name Lenmeldy in March 2024.2
REFERENCES
1. Calbi V, Fumagalli F, De Mattia F, et al. AtidarsageneAutotemcel (Hematopoietic Stem Cell GeneTherapy) Preserves Cognitive and Motor Development in Metachromatic Leukodystrophy with up to 12 Years Follow-Up. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #1
2. FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy. News release. Orchard Therapeutics. March 18, 2024. Accessed March 18, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-children-metachromatic-leukodystroph
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025